New Combination Therapy Eliminates Pancreatic Tumours in Mice, Raising Fresh Hope

ପାଣିପାଗ

ପଶ୍ଚିମ ଓଡ଼ିଶାରେ ୪୫ ଡିଗ୍ରୀ ଛୁଇଁଲା ତାପମାତ୍ରା; ସୁବର୍ଣ୍ଣପୁରରେ ଅସହ୍ୟ...

May 25, 2026

ଆହୁରି ବଢ଼ିବ ଓଡ଼ିଶାର ଗ୍ରୀଷ୍ମ ପ୍ରକୋପ; କେତେକ ଜିଲ୍ଲାକୁ ରେଡ୍‌...

May 25, 2026

ଆଗାମୀ ସପ୍ତାହରେ ଓଡ଼ିଶାରେ ଗରମ ସହ କାଳବୈଶାଖୀ ପ୍ରଭାବ, ତାପପ୍ରବାହ...

May 25, 2026

ମେ’ ୧୧ ପାଖାପାଖି ବଙ୍ଗୋପସାଗରରେ ନୂଆ ଲଘୁଚାପ ସମ୍ଭାବନା, ପାଣିପାଗ...

May 09, 2026

ଶିକ୍ଷା

ନିଟ୍-ୟୁଜି ୨୦୨୬ ପେପର ଲିକ୍‌ ମାମଲା: ‘ଏନଟିଏ କିଛି ଶିଖିନି’...

May 25, 2026

NEET UG 2026 ପେପର୍‌ ବିଶ୍ଳେଷଣ: Biology ଲମ୍ବା, Physics...

May 05, 2026

JEE Advanced 2026 ପଞ୍ଜିକରଣ ସମୟସୀମା ବଢ଼ାଇଲା IIT ରୁଡ଼କୀ,...

May 05, 2026

CBSEର କଡ଼ା ନିର୍ଦ୍ଦେଶ, ମଇ 31 ସୁଦ୍ଧା ଷଷ୍ଠ ଶ୍ରେଣୀର...

May 05, 2026

New Combination Therapy Eliminates Pancreatic Tumours in Mice, Raising Fresh Hope

Scientists in Spain have developed a novel combination therapy that completely eliminated pancreatic tumours in mice. While still in early stages, the breakthrough adds to growing optimism around new immunotherapy and vaccine-based treatments for one of the deadliest cancers.

Published by Somesh | January 30, 2026

Pancreatic cancer remains one of the most lethal malignancies, with nearly 90 percent of patients dying within five years of diagnosis due to late detection and limited treatment options. However, new research from Spain is offering cautious optimism.

Scientists at the Spanish National Cancer Research Centre (CNIO) have designed an experimental combination therapy that successfully eliminated pancreatic tumours in mouse models without significant side effects. The study, published in the journalProceedings of the National Academy of Sciences (PNAS), combines multiple immunotherapy approaches, including a cancer vaccine with immune-boosting adjuvants and checkpoint inhibitors.

The therapy targets the cancer’s natural resistance mechanisms by blocking the KRAS oncogene at three different points in its signalling pathway. KRAS mutations are present in nearly 90 percent of pancreatic cancer cases and are a major reason why existing treatments often fail. By attacking the pathway at multiple levels, researchers were able to prevent tumours from developing resistance and eliminate them permanently in mice.

The findings come shortly after encouraging results from an early human trial of a personalised mRNA pancreatic cancer vaccine in the United States, further strengthening interest in combination and vaccine-driven therapies. While the Spanish research is still far from human clinical trials, experts believe it represents an important step toward improving survival outcomes for pancreatic ductal adenocarcinoma, the most common form of the disease.